Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rhythm Pharmaceuticals, Inc. Common Stock

RYTM

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Last trade $117.04
Day change +$9.56 (+8.89%)
Day range $104.26 – $118.25
Volume 1,898,165
Market cap $7.45B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$7.45B
Price / earnings
—
Price / book
36.97×
Price / sales
26.54×
EV / sales
26.77×
EV / EBITDA
-40.35×

Profitability

Earnings per share
-$2.86
Return on assets
-44.75%
Return on equity
-98.39%
Dividend yield
0.02%

Liquidity and leverage

Debt / equity
0.51×
Current ratio
2.78×
Quick ratio
2.57×
Cash ratio
0.26×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$83.24M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RYTM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$92.13M$71.26M$60.11M$57.25M$51.3M$48.5M$32.7M$41.83M
Cost of revenue$12.17M$8.93M$7.16M$4.8M$5.5M$5.54M$3.65M$3.79M
Gross profit$79.96M$62.32M$52.96M$52.45M$45.8M$42.96M$29.06M$38.04M
Selling, general and administrative$66.75M$67.45M$63.59M$57.48M$52.43M$45.95M$39.09M$38.13M
Research and development$52.48M$43.43M$41.73M$42.03M$46.03M$42.31M$36.97M$41.17M
Total operating expenses$119.23M$110.88M$105.32M$99.51M$98.45M$88.26M$76.06M$79.3M
Operating income-$39.27M-$48.55M-$52.36M-$47.06M-$52.65M-$45.3M-$47M-$41.26M
Interest expense-$4.5M-$4.54M-$4.58M-$4.62M-$4.74M-$5.82M-$5.41M-$5.45M
Income before taxes-$40.76M-$48.85M-$55.09M-$47.54M-$52.79M-$46.3M-$49.42M-$43.38M
Income taxes$610K$444K$545K-$31K$111K$337K$80K-$90K
Net income-$41.37M-$49.3M-$55.64M-$47.51M-$52.9M-$46.63M-$49.5M-$43.29M
Net income attributable to common shareholders-$42.35M-$50.36M-$56.74M-$48.84M-$54.28M-$47.98M-$50.82M-$44.63M
EBITDA-$39.02M-$48.3M-$52.11M-$46.79M-$52.35M-$44.92M-$46.62M-$40.87M
Basic earnings per share-$0.61-$0.73-$0.83-$0.73-$0.82-$0.75-$0.81-$0.72
Diluted earnings per share-$0.61-$0.73-$0.83-$0.73-$0.82-$0.75-$0.81-$0.72

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals announced that the UK's National Institute for Health and Care Excellence (NICE) has expanded its positive guidance for IMCIVREE (setmelanotide) to include adults with genetically confirmed Bardet-Biedl syndrome, allowing NHS funding for this patient population. The expansion builds on previous 2024 guidance that covered patients ages 6-17 and recognizes the significant burden of hyperphagia and obesity associated with the disease throughout adulthood.

Zacks Investment Research

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates

Rhythm Pharmaceuticals reported a Q3 loss of $0.61 per share, beating consensus estimates of $0.68 loss, with a 10.29% earnings surprise. Revenue reached $92.13 million, surpassing estimates by 9.07% and nearly doubling year-ago revenues of $51.3 million. However, the stock has underperformed the market, down 12.7% year-to-date versus the S&P 500's 10.2% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

GlobeNewswire Inc.

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

Rhythm Pharmaceuticals amended its global licensing agreement with LG Chem for bivamelagon, reducing royalties from low-to-mid-single digits to 1% on MC4R agonist sales while committing to $350 million in fixed payments over four years. The company also secured a $750 million term-loan facility led by KKR's HealthCare Royalty and Blackstone to support the agreement, commercialization efforts, and pipeline development.

Zacks Investment Research

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +1.38% and Zacks Rank #3. The company is projected to report a quarterly loss of $0.68 per share (improved from $0.81 year-ago) with revenues of $84.47 million, up 64.7% year-over-year. The stock has beaten consensus EPS estimates in 3 of the last 4 quarters.

GlobeNewswire Inc.

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan following MHLW approval and inclusion on Japan's National Health Insurance drug price list. IMCIVREE is the first approved therapy in Japan for acquired hypothalamic obesity, with an estimated patient population of 5,000-8,000 people. The approval was supported by Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.